Your browser doesn't support javascript.
Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review.
Keshavarz, Pedram; Yazdanpanah, Fereshteh; Rafiee, Faranak; Mizandari, Malkhaz.
  • Keshavarz P; Department of Diagnostic & Interventional Radiology of New Hospitals LTD, 12 Krtsanisi, 0114 Tbilisi, Georgia; Department of Radiology, Tbilisi State Medical University (TSMU), Tbilisi, Georgia.
  • Yazdanpanah F; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tabriz, Iran.
  • Rafiee F; Department of Radiology, Medical Imaging Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Mizandari M; Department of Diagnostic & Interventional Radiology of New Hospitals LTD, 12 Krtsanisi, 0114 Tbilisi, Georgia; Department of Radiology, Tbilisi State Medical University (TSMU), Tbilisi, Georgia. Electronic address: mgmizandari@gmail.com.
Acad Radiol ; 28(8): 1058-1071, 2021 08.
Article in English | MEDLINE | ID: covidwho-1227955
ABSTRACT
RATIONALE AND

OBJECTIVES:

Despite all the benefits and effectiveness of the coronavirus disease 2019 (COVID-19) vaccines mentioned in recent clinical trials, some post-vaccination side effects such as lymphadenopathy (LAP) were observed. The present study reviewed all studies with imaging findings presentation of LAP after COVID-19 vaccination. MATERIALS AND

METHODS:

We conducted a literature search in online databases, including Scopus, Medline (PubMed), Web of Science, Embase (Elsevier), Cochrane library, and Google Scholar.

RESULTS:

A total of 19 studies (68 cases), including 60 (88.2%) females and eight (11.8%) males with a presentation of LAP after COVID-19 vaccination, were reviewed. LAP was identified after first or second dosages of three types of COVID-19 vaccines, including Pfizer-BioNTech (n = 30, 44.1%), Moderna (n = 17, 25%), and Oxford-AstraZeneca (n = 1, 1.5%). In 20 (29.4%) cases, vaccine type was not reported or only reported as mRNA COVID-19 vaccine. The median days of LAP presentation after the first and second dosages of COVID-19 vaccination, were 12 and 5 days, respectively. Most of the LAP imaging findings related to COVID-19 vaccination (n = 66, 97%) were seen from first day to 4 weeks after vaccination. However, LAP remained after 5 and 6 weeks of the first and second dosages of COVID-19 vaccination with decreased lymph nodes' size and residual cortical thickening in two cases.

CONCLUSION:

This review study of cases with LAP-associated COVID-19 vaccination guides radiologists and physicians to rely on patient's clinical context and updated resources to prevent potential disease upstaging and change in therapy.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccination / Lymphadenopathy / COVID-19 Vaccines / COVID-19 Type of study: Observational study / Prognostic study / Reviews Topics: Vaccines Limits: Female / Humans / Male Language: English Journal: Acad Radiol Journal subject: Radiology Year: 2021 Document Type: Article Affiliation country: J.acra.2021.04.007

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccination / Lymphadenopathy / COVID-19 Vaccines / COVID-19 Type of study: Observational study / Prognostic study / Reviews Topics: Vaccines Limits: Female / Humans / Male Language: English Journal: Acad Radiol Journal subject: Radiology Year: 2021 Document Type: Article Affiliation country: J.acra.2021.04.007